poisar

Stocks · News reference

Boston Scientific Announces Positive Results from SIMPLAAFY Clinical Trial

Fiscal.ai

Boston Scientific reported positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial of its WATCHMAN FLX Pro Left Atrial Appendage Closure device.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncResearchandmarkets.Com

    Global Sacral Neuromodulation Market Size, Share, Trends and Forecast 2026-2036: Rechargeable, MRI-Compatible Systems Drive 11.1% CAGR

    The global sacral neuromodulation market is estimated at USD 1.37 billion in 2026 and projected to reach USD 3.92 billion by 2036, growing at 11.1% CAGR. Market expansion is driven by rising prevalence of urinary and fecal incontinence, aging populations, and technological advancements in rechargeable and MRI-compatible devices. Key challenges include high procedural costs and complex regulatory requirements. North America leads the market while Asia-Pacific is expected to register the fastest growth.